Hemispherx BioPharma (NYSEAMERICAN:HEB) Share Price Crosses Above 200 Day Moving Average – Time to Sell?
by Danessa Lincoln · The Markets DailyHemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.70 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares traded.
Hemispherx BioPharma Stock Performance
The stock’s fifty day simple moving average is $6.70 and its two-hundred day simple moving average is $6.70.
Hemispherx BioPharma Company Profile
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments.
Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts.